R7E.F Cybin Inc.

Healthcare Biotechnology Frankfurt Exchange
10.88 EUR
Close of Nov 12, 2026
3.08 13.36
Market cap
EUR 795M
P/E
-
P/B
2.67x
ROE
-79.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is R7E.F undervalued?

Graham number

The Graham number of Cybin Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cybin Inc. fundamental analysis

No fundamental analysis for Cybin Inc. yet.

Cybin Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cybin Inc.

Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product inc…

Full company profile